Lipid levels and risk-stratified management gaps of dyslipidemia in China
BACKGROUND: Dyslipidemia remains a major modifiable contributor to China's cardiovascular disease (CVD) burden, yet large-scale evidence on risk-stratified management gaps is lacking. METHODS: In this nationwide study across 1,785 hospitals in 28 Chinese provinces, 604,250 outpatients with dyslipidemia were enrolled. We analyzed lipid levels, quantified control rate among treated population and rates of requiring lipid-lowering therapy (LLT) among untreated population across regions, socioeconomic status, and demographic groups. RESULTS: Total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels were higher among females, middle-aged individuals, and individuals with obesity. LDL-C levels were also higher among urban residents, while TC showed no significant urban-rural difference. Triglyceride (TG) levels were higher in males, middle-aged individuals, individuals with obesity, and rural residents. Among treated population, LDL-C/non-HDL-C control rates reached 95% in low-risk, 70-90% in moderate-risk, 40-50% in high-risk, and 5-15% in very-high-risk groups. Among untreated population, rates of requiring LLT reached about 20% in the low-risk group and over 70% in moderate- and high-risk groups. After adjusting for covariates, males, older individuals, smokers, patients with hypertension or type 2 diabetes mellitus, as well as those in rural and low-gross-domestic-product areas were associated with lower lipid control rates and higher treatment needs. CONCLUSIONS: Our findings highlight the urgent need for risk-stratified lipid management in primary care, improved access to LLT, and policies addressing regional and socioeconomic disparities to enhance lipid control and reduce CVD burden in China. Lessons from China can inform global strategies to improve lipid management and reduce the CVD burden.
Authors
- Yaokun Liu (ORCID: https://orcid.org/0009-0006-4526-5709)
- M Zhang
- X F Liu
- Shengcong Liu
- Jingwei Bian
- Shuduo Zhou (ORCID: https://orcid.org/0000-0002-5463-3116)
- Junguo Jin (ORCID: https://orcid.org/0000-0001-8962-8002)
- FU Zhenyan
- Yanwen Qin
- Zuoyi Zhou (ORCID: https://orcid.org/0000-0002-8687-9196)
- Yan Chen (ORCID: https://orcid.org/0000-0003-0961-8897)
- Yuxi Li (ORCID: https://orcid.org/0000-0003-1556-598X)
- Rujie Zheng
- Haoyu Weng (ORCID: https://orcid.org/0009-0006-6318-5817)
- Yixue Zhao (ORCID: https://orcid.org/0000-0002-3880-0105)
- Leyi Wang
- Z Liu
- J Jia
- J P Li
- Tieci Yi
- Chao Zhai
- M G Zhou
- Yangyang Sun
- Luya Wang
- Long Zhang
- Fangfang Fan
- Hu Ding
- Yan Zhang
Institutions
- Xinjiang Medical University (CN)
- Peking University (CN)
- First Affiliated Hospital of Xinjiang Medical University (CN)
- National Center for Chronic and Noncommunicable Disease Control and Prevention (CN)
- Suzhou Municipal Hospital (CN)
- Beijing Anzhen Hospital (CN)
- Peking University First Hospital (CN)
- Tongji Hospital (CN)
Publication Details
- Journal
- BMC Medicine
- Published
- 2026-05-02
- DOI
- https://doi.org/10.1186/s12916-026-04904-x
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Key Research and Development Program of China